<DOC>
	<DOCNO>NCT00004112</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know whether combination chemotherapy plus rituximab effective combination chemotherapy alone non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without rituximab treat patient newly diagnose non-Hodgkin 's lymphoma treat previously .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Patients With Newly Diagnosed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether addition rituximab cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) increase failure-free survival patient newly diagnose , previously untreated , aggressive B-cell non-Hodgkin 's lymphoma . II . Determine whether addition rituximab change toxicity profile attribute CHOP chemotherapy patient population . OUTLINE : This randomize , multicenter study . Patients stratify center , histology ( diffuse small cleave cell , diffuse mixed , diffuse large cell v immunoblastic large cell , mantle cell , marginal zone ) , risk group ( low v intermediate v high ) . Patients enter one two treatment arm : Arm I : Patients receive rituximab IV day 1 , follow cyclophosphamide IV , doxorubicin IV , vincristine IV , oral prednisone 5 consecutive day begin day 3 . Arm II : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV , oral prednisone daily 5 consecutive day begin day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow 3 year . PROJECTED ACCRUAL : A total 270 patient ( 135 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , newly diagnose , aggressive ( stage IIIV ) Bcell nonHodgkin 's lymphoma , include limited : Mantle cell Diffuse large cell Diffuse mix cell Anaplastic large cell ( Bcell type ) Diffuse small cleave cell Marginal zone lymphoma No prior Tcell lymphoma CD20 positive PATIENT CHARACTERISTICS : Age : 19 Performance status : WHO 02 Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count great 1,000/mm3 ( unless due nonHodgkin 's lymphoma ( NHL ) bone marrow involvement ) Hepatic : Unless due NHL : Bilirubin le 3.0 mg/dL Alkaline phosphatase less 3 time upper limit normal ( ULN ) SGOT le 3 time ULN Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No serious disease medical condition would interfere compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid ( unless prevention nausea vomit ) Nonsteroidal hormones nonlymphoma related condition allow ( e.g. , insulin diabetes ) Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage II mantle cell lymphoma</keyword>
	<keyword>stage II small lymphocytic lymphoma</keyword>
	<keyword>stage II marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>